BIO-TECHNE CorpTECH

時価総額
$131.7億
PER
58.8倍
2012年
6月30日
2013年
6月30日
2014年
6月30日
2015年
6月30日
2016年
6月30日
2017年
6月30日
2018年
6月30日
2019年
6月30日
2020年
6月30日
2021年
6月30日
2022年
6月30日
2023年
6月30日
Net earnings, including noncontrolling interest---------140263285
Depreciation and amortization12121937436064788388101107
Costs recognized on sale of acquired inventory85775324-220
Deferred income taxes--------1413-277-30
us-gaap_ShareBasedCompensation---6915283232494239
Fair value adjustment to contingent consideration payable-----1820-2-15-20-12
Contingent consideration payments------13-27--1-0-3-
(Gain) Loss on investment, net------04---37
Fair value adjustment on available-for-sale investments-------16-13868-15-0
(Gain) loss on equity method investment-11----------1
Asset impairment restructuring----------1-
Eminence impairment----------19-
Gain on sale of Eminence-----------12
Leases, net--------00-12
Other operating activity------12-1-010
Trade accounts and other receivables, net22-1122320315-7165821
Inventories22357113141573230
Prepaid expenses001620,000381,0002-313135
Increase (Decrease) in Accounts Payable and Accrued Liabilities20129656101913-8
Salaries, wages and related accruals1-01262-053218-25
Income taxes payable-2-1-22298,000110-10-7133-2
Net cash provided by (used in) operating activities127124----170182205352325254
Proceeds from maturities of available-for-sale investments67625913776,00063622147662635
Purchases of available-for-sale investments----------5321
Proceeds from sale of CCXI investment-----------73
Additions to property and equipment62214201715212552444538
Acquisitions, net of cash acquired--1094209125468289-225-101
Investment in unconsolidated entity, net-------22--21--
Proceeds from sale of Eminence-----------18
Investment of forward purchase contract----------25-
Investment in Wilson Wolf-----------232
Net cash provided by (used in) investing activities-22-31-----39-33727-244-97-266
Cash dividends414345474847484849505050
Proceeds from stock option exercises1181055193871657730
Re-purchases of common stock242-----15504316120
Borrowings under line-of-credit agreement----77369555804025690620
Repayments of long-term debt---955911760414189272176526
Contingent consideration payments - financing-----2162-3-1-
Taxes paid on RSUs and net share settlements----------2329
Other financing activity-------4-6-4-191-2
Net cash provided by (used in) financing activities-65-45-----99134-184-63-24323
Effect of exchange rate changes on cash and cash equivalents---------36-12-3
Net change in cash and cash equivalents--------4652-278